Anti-CD3/anti-CD84 bispecific T-cell engager (Shanghai Symray Biopharma)

N/A

Report date: 2026/03/19 20:00:18

Base Information

Drug NameAnti-CD3/anti-CD84 bispecific T-cell engager (Shanghai Symray Biopharma)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionCD3 T-cell engagersLeukocyte Antigen CD84 modulators

TargetsT cell surface glycoprotein CD3Leukocyte Antigen CD84

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesSymRay Biopharma LLC

China Registration ClassN/A

Develop Information

Active CompaniesSymRay Biopharma LLC

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A